Baird Upgrades Vor Biopharma, Inc. (VOR) to Outperform

Baird analyst Jack Allen upgraded Vor Biopharma, Inc. (NASDAQ: VOR) from Neutral to Outperform with a price target of $64.00 (from $20.00).

The analyst commented: "Upgrading to Outperform. We're impressed by the existing dataset surrounding telitacicept, a novel APRIL/BAFF bispecific. To that end, we note the large amount of data from RemeGen's development of telitacicept in China (where telitacicept has produced positive results in five Phase 3s) derisks Vor's ex-China development ambitions, and appear to suggest best-in-disease potential in both gMG and pSD (Vor's current lead indications). Looking ahead, we anticipate investor enthusiasm for telitacicept in gMG and pSD should continue to build with a pair of late-October data updates in the coming weeks."

For an analyst ratings summary and ratings history on Vor Biopharma, Inc. click here. For more ratings news on Vor Biopharma, Inc. click here.

Shares of Vor Biopharma, Inc. closed at $32.29 yesterday.

You May Also Be Interested In

• Mizuho Remain Buyers of Lumentum (LITE) Into EPS
• Corteva Inc. (CTVA) PT Raised to $100 at BMO Capital 'Despite Overreaction'
• Evercore ISI: 'we reiterate our TAP Outperform on TTD ahead of the Q2 earnings report'